Unicycive Therapeutics (UNCY)
NASDAQ:UNCY
UNCY Stock Chart & Stats
$6.93
-$0.03(-4.01%)
At close: 4:00 PM EST
$6.93
-$0.03(-4.01%)
Day’s Range― - ―
52-Week Range$3.71 - $11.00
Previous CloseN/A
Volume1.16M
Average Volume (3M)499.19K
Market Cap
$174.90M
Enterprise Value$119.85M
Total Cash (Recent Filing)$41.27M
Total Debt (Recent Filing)$117.00K
Price to Earnings (P/E)―
Beta1.74
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding25,237,782
10 Day Avg. Volume542,719
30 Day Avg. Volume499,185
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)30.36
Price to Sales (P/S)0.00
P/FCF Ratio-29.25
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-439.03
Enterprise Value/Ebitda-4.63
Forecast
1Y Price Target
$56.80Price Target Upside719.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.28
Revenue Forecast (FY)$80.68M
Bulls Say, Bears Say
Bulls Say
Commercial PreparednessManagement is building commercial infrastructure by hiring key leaders, arranging contingent contracts with sales representatives, and establishing a patient hub to identify patients and support an initial launch across concentrated prescribers.
Regulatory OutlookFDA acceptance of the new drug application resubmission and a Class II designation, with prior regulator concerns limited to a third-party manufacturer's processes rather than clinical data, significantly de-risks the approval pathway for the lead candidate.
Reimbursement PathwayPursuit of a Transitional Drug Add-on Payment Adjustment could secure favorable Medicare reimbursement and allow premium pricing, improving commercial economics and increasing appeal to potential acquirers.
Bears Say
Commercial Execution RiskTransitioning from a clinical-stage developer to a commercial-scale organization creates execution risk where ineffective sales deployment or operational gaps could slow adoption and revenue generation.
Financing And Dilution RiskFuture funding needs could require additional equity issuance, introducing potential dilution that may reduce shareholder value despite current cash on hand.
Legal And Intellectual Property RiskLegal or intellectual property challenges could emerge that threaten exclusivity or result in costly litigation, undermining the drug's market potential.
Unicycive Therapeutics News
UNCY FAQ
What was Unicycive Therapeutics’s price range in the past 12 months?
Unicycive Therapeutics lowest stock price was $3.71 and its highest was $11.00 in the past 12 months.
What is Unicycive Therapeutics’s market cap?
Unicycive Therapeutics’s market cap is $174.90M.
When is Unicycive Therapeutics’s upcoming earnings report date?
Unicycive Therapeutics’s upcoming earnings report date is May 19, 2026 which is in 44 days.
How were Unicycive Therapeutics’s earnings last quarter?
Unicycive Therapeutics released its earnings results on Mar 30, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.512 by $0.192.
Is Unicycive Therapeutics overvalued?
According to Wall Street analysts Unicycive Therapeutics’s price is currently Undervalued.
Does Unicycive Therapeutics pay dividends?
Unicycive Therapeutics does not currently pay dividends.
What is Unicycive Therapeutics’s EPS estimate?
Unicycive Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Unicycive Therapeutics have?
Unicycive Therapeutics has 25,237,782 shares outstanding.
What happened to Unicycive Therapeutics’s price movement after its last earnings report?
Unicycive Therapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.512. Following the earnings report the stock price went down -4.382%.
Which hedge fund is a major shareholder of Unicycive Therapeutics?
Currently, no hedge funds are holding shares in UNCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Unicycive Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.80 (719.62% Upside)
$56.80 (719.62% Upside)
Blogger Sentiment
Bullish
UNCY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 263.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 12.9%
Last 30 Days ▲ 12.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.34%
12-Months-Change
Fundamentals
Return on Equity
-111.37%
Trailing 12-Months
Asset Growth
55.16%
Trailing 12-Months
Company Description
Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
UNCY Stock 12 Month Forecast
Average Price Target
$56.80
▲(719.62% Upside)
Technical Analysis
Ownership Overview
21.10%
Insiders
3.61% Mutual Funds
25.54% Other Institutional Investors
46.21% Public Companies and
Individual Investors